RE:RE:RE:1 Patient enrolled per month..Hi MM. In my mind the ultimate price for the FDA approved completed phase 3 EAA/PMX is a finite number. Obviously all the influencing factors in the world that change with time (size of market, competition, inflation, expected returns) would affect that number. So it could go up or done with market forces.
And we are less than 100% done as the choir went to great lengths to point out this morning. So to answer your question the price in my mind is lower than what we get when it's 100% done and rises from now until 100%. For instance if we're say 60% there and the ultimate value is $10 then $6 would be today's value on a very simplistic basis. As the trial progresses with more patients done the percentage rises and consequently the value.
My point is that Baxter/KidneyCo has identified EXX/PMX as a significant part of their new KidneyCo initiative to create value for Baxter shareholders. And Spectral management and BOD can't stop that train from getting to its destination. All they affect now is how far we get towards 100% before Baxter/KidneyCo get the keys and drive away.